# Clinical trial results:
# A Modular Phase IIa Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients with Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)

## Summary

| | |
|---|---|
| EudraCT number | 2020-002529-27 |
| Trial protocol | FR |
| Global end of trial date | |

**Results information**

| | |
|---|---|
| Result version number | v1 (current) |
| This version publication date | 25 February 2026 |
| First version publication date | 25 February 2026 |

## Trial information

**Trial identification**

| | |
|---|---|
| Sponsor protocol code | D5339C00001 |

**Additional study identifiers**

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT04564027 |
| WHO universal trial number (UTN) | - |

Notes:

**Sponsors**

| | |
|---|---|
| Sponsor organisation name | AstraZeneca Clinical Study Information Center |
| Sponsor organisation address | Södertälje, Södertälje, Sweden, 151 85 |
| Public contact | AstraZeneca Clinical study Information Center, AstraZeneca Clinical study Information Center, +1 8772409479, information.center@astrazeneca.com |
| Scientific contact | Global Clinical Lead, AstraZeneca Clinical Study Information Center, +1 8772409479, information.center@astrazeneca.com |

Notes:

**Paediatric regulatory details**

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Interim |
| Date of interim/final analysis | 28 April 2023 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 28 April 2023 |
| Global end of trial reached? | No |

Notes:

## General information about the trial

Main objective of the trial:

To obtain a preliminary assessment of the efficacy of ceralasertib in participants with Ataxia telangiectasia mutated (ATM)-altered advanced solid tumour (aST) refractory to standard treatments options, as assessed by Objective response rate (ORR).

Protection of trial subjects:

This study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with the International Conference on Harmonisation/Good Clinical Practice, applicable regulatory requirements, and the AstraZeneca policy on Bioethics and Human Biological Samples. Before enrollment of any patient into the study, the final protocol, including the final version of the informed consent form, was approved by the national regulatory authority or a notification to the national regulatory authority was done, according to local regulations.

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 01 December 2020 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Spain: 5 |
| Country: Number of subjects enrolled | France: 19 |
| Country: Number of subjects enrolled | United States: 30 |
| Worldwide total number of subjects | 54 |
| EEA total number of subjects | 24 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 17 |
| From 65 to 84 years | 37 |

| | |
|---|---|
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details:

Participants were enrolled in this study from 01 December 2020 to 04 April 2023 at 18 centers in 3 countries.

### Pre-assignment

Screening details:

The screening comprised of 2 parts, Part 1 and Part 2, which applied for both Cohort A and Cohort B. Participants meeting the inclusion criteria were enrolled in the study. All the assessments were performed as per the schedule of the assessments.

### Period 1

| | |
|---|---|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Cohort A (aST): 240 mg of Ceralasertib |

Arm description:

Participants with Ataxia telangiectasia mutated (ATM) altered Advanced solid tumour (aST) received 240 mg of ceralasertib twice daily from Day 1 to Day 14 of 28 days cycle.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | 240 mg of Ceralasertib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants received 240 mg of ceralasertib in the Cohort A of the study

| | |
|---|---|
| **Arm title** | Cohort A (aST): 160 mg of Ceralasertib |

Arm description:

Participants with ATM-altered aST received 160 mg of ceralasertib twice daily from Day 1 to Day 14 of 28 days cycle.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | 160 mg of ceralasertib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants received 160 mg of ceralasertib in the Cohort A of the study

| | |
|---|---|
| **Arm title** | Cohort B (mCRPC): 240 mg of Ceralasertib |

Arm description:

Participants with ATM-altered Metastatic castration-resistant prostate cancer (mCRPC) received 240 mg of ceralasertib twice daily from Day 1 to Day 14 of 28 days cycle.

| | |
|---|---|
| Arm type | Experimental |

| | |
|---|---|
| Investigational medicinal product name | 240 mg of ceralasertib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants received 240 mg of ceralasertib in the Cohort B of the study

| **Arm title** | Cohort B (mCRPC): 160 mg of Ceralasertib |
|---|---|

Arm description:

Participants with ATM-altered mCRPC received 160 mg of ceralasertib twice daily from Day 1 to Day 14 of 28 days cycle.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | 160 mg of ceralasertib |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants received 160 mg of ceralasertib in the Cohort B of the study

| **Number of subjects in period 1** | Cohort A (aST): 240 mg of Ceralasertib | Cohort A (aST): 160 mg of Ceralasertib | Cohort B (mCRPC): 240 mg of Ceralasertib |
|---|---|---|---|
| Started | 8 | 30 | 1 |
| Completed | 8 | 27 | 1 |
| Not completed | 0 | 3 | 0 |
| Ongoing treatment as of 28Apr23 | - | 3 | - |

| **Number of subjects in period 1** | Cohort B (mCRPC): 160 mg of Ceralasertib |
|---|---|
| Started | 15 |
| Completed | 15 |
| Not completed | 0 |
| Ongoing treatment as of 28Apr23 | - |

## Baseline characteristics

| Reporting groups | |
|---|---|
| Reporting group title | Cohort A (aST): 240 mg of Ceralasertib |
| Reporting group description: | |
| Participants with Ataxia telangiectasia mutated (ATM) altered Advanced solid tumour (aST) received 240 mg of ceralasertib twice daily from Day 1 to Day 14 of 28 days cycle. | |
| Reporting group title | Cohort A (aST): 160 mg of Ceralasertib |
| Reporting group description: | |
| Participants with ATM-altered aST received 160 mg of ceralasertib twice daily from Day 1 to Day 14 of 28 days cycle. | |
| Reporting group title | Cohort B (mCRPC): 240 mg of Ceralasertib |
| Reporting group description: | |
| Participants with ATM-altered Metastatic castration-resistant prostate cancer (mCRPC) received 240 mg of ceralasertib twice daily from Day 1 to Day 14 of 28 days cycle. | |
| Reporting group title | Cohort B (mCRPC): 160 mg of Ceralasertib |
| Reporting group description: | |
| Participants with ATM-altered mCRPC received 160 mg of ceralasertib twice daily from Day 1 to Day 14 of 28 days cycle. | |

| **Reporting group values** | Cohort A (aST): 240 mg of Ceralasertib | Cohort A (aST): 160 mg of Ceralasertib | Cohort B (mCRPC): 240 mg of Ceralasertib |
|---|---|---|---|
| Number of subjects | 8 | 30 | 1 |
| Age Categorical<br>Units: Participants | | | |
| 18-64 | 3 | 11 | 0 |
| 65-84 | 5 | 19 | 1 |
| ≥ 85 | 0 | 0 | 0 |
| Age continuous<br>Units: years | | | |
| arithmetic mean | 64.1 | 65.5 | 0 |
| standard deviation | ± 10.92 | ± 11.0 | ± 0 |
| Sex: Female, Male<br>Units: Participants | | | |
| Female | 5 | 14 | 0 |
| Male | 3 | 16 | 1 |
| Race/Ethnicity, Customized<br>Units: Subjects | | | |
| Black or African American | 0 | 0 | 0 |
| Native Hawaiin or Other Pacific Islander | 0 | 0 | 0 |
| White | 8 | 11 | 0 |
| Not Reported | 0 | 7 | 0 |
| Missing | 0 | 9 | 0 |
| Other | 0 | 3 | 1 |
| Race/Ethnicity, Customized<br>Units: Subjects | | | |
| Hispanic or Latino | 0 | 3 | 0 |
| Not Hispanic or Latino | 8 | 13 | 1 |
| Missing. | 0 | 14 | 0 |

| **Reporting group values** | Cohort B (mCRPC): 160 mg of Ceralasertib | Total | |
|---|---|---|---|
| Number of subjects | 15 | 54 | |
| Age Categorical<br>Units: Participants | | | |
| 18-64 | 3 | 17 | |
| 65-84 | 12 | 37 | |
| ≥ 85 | 0 | 0 | |
| Age continuous<br>Units: years | | | |
| arithmetic mean | 70.7 | | |
| standard deviation | ± 7.46 | - | |
| Sex: Female, Male<br>Units: Participants | | | |
| Female | 0 | 19 | |
| Male | 15 | 35 | |
| Race/Ethnicity, Customized<br>Units: Subjects | | | |
| Black or African American | 0 | 0 | |
| Native Hawaiin or Other Pacific Islander | 0 | 0 | |
| White | 6 | 25 | |
| Not Reported | 4 | 11 | |
| Missing | 5 | 14 | |
| Other | 0 | 4 | |
| Race/Ethnicity, Customized<br>Units: Subjects | | | |
| Hispanic or Latino | 1 | 4 | |
| Not Hispanic or Latino | 9 | 31 | |
| Missing. | 5 | 19 | |

## End points

### End points reporting groups

| | |
|---|---|
| Reporting group title | Cohort A (aST): 240 mg of Ceralasertib |
| Reporting group description: | |
| Participants with Ataxia telangiectasia mutated (ATM) altered Advanced solid tumour (aST) received 240 mg of ceralasertib twice daily from Day 1 to Day 14 of 28 days cycle. | |
| Reporting group title | Cohort A (aST): 160 mg of Ceralasertib |
| Reporting group description: | |
| Participants with ATM-altered aST received 160 mg of ceralasertib twice daily from Day 1 to Day 14 of 28 days cycle. | |
| Reporting group title | Cohort B (mCRPC): 240 mg of Ceralasertib |
| Reporting group description: | |
| Participants with ATM-altered Metastatic castration-resistant prostate cancer (mCRPC) received 240 mg of ceralasertib twice daily from Day 1 to Day 14 of 28 days cycle. | |
| Reporting group title | Cohort B (mCRPC): 160 mg of Ceralasertib |
| Reporting group description: | |
| Participants with ATM-altered mCRPC received 160 mg of ceralasertib twice daily from Day 1 to Day 14 of 28 days cycle. | |

### Primary: Cohort A (aST): Objective response rate (ORR)

| | |
|---|---|
| End point title | Cohort A (aST): Objective response rate (ORR)[1][2] |
| End point description: | |
| ORR is defined as the percentage of participants who have at least one response of complete response (CR) or partial response (PR) prior to any evidence of progression (as defined by response evaluation criteria in solid tumours [RECIST] 1.1) that is confirmed at least 4 weeks later. The CR is defined as disappearance of all target and non-target lesions and no new lesions. The PR is defined as >= 30% decrease in the sum of the diameters of target lesions compared to baseline and no new non-target lesion. Evaluable for response set included all participants who were Molecularly Eligible Centrally Confirmed evaluable for response set with measurable disease at baseline and who received at least 1 dose of study intervention. Due to an increased frequency and early onset of Grade≥3 hematological toxicity on receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg were not included in the efficacy analyses for both study cohorts. | |
| End point type | Primary |
| End point timeframe: | |
| 2 years 4 months | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No formal hypothesis testing was conducted and therefore has not been presented here.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No formal hypothesis testing was conducted and therefore has not been presented here.

| End point values | Cohort A (aST): 160 mg of Ceralasertib | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 28 | | | |
| Units: Percentage of participants | | | | |
| number (confidence interval 80%) | 7.14 (1.9 to 17.9) | | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Cohort B (mCRPC): Composite response rate

| End point title | Cohort B (mCRPC): Composite response rate[3][4] |
|---|---|

End point description:

Composite response rate is defined as the investigator assessed radiological response by RECIST 1.1 for soft tissue and visceral lesions and Prostate Cancer Working Group 3 (PCWG3) for bone lesions, confirmed prostate specific antigen (PSA) decline of more than 50%, and/or confirmed circulating tumour cell [CTC] conversion from unfavorable (>=5 cells/7.5 ml blood) to favorable (<5 cells). Evaluable for response set included all participants who were Molecularly Eligible Centrally Confirmed evaluable for response set with measurable disease at baseline and who received at least 1 dose of study intervention.
Due to an increased frequency and early onset of Grade≥3 hematological toxicity noted among the participants receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg BID starting dose were not included in the efficacy analyses for both study cohorts.

| End point type | Primary |
|---|---|

End point timeframe:

Up to 2 years 4 months

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No formal hypothesis testing was conducted and therefore has not been presented here.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No formal hypothesis testing was conducted and therefore has not been presented here.

| **End point values** | Cohort B (mCRPC): 160 mg of Ceralasertib | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 13 | | | |
| Units: Percentage of participants | | | | |
| number (confidence interval 80%) | 7.7 (0.8 to 26.8) | | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Cohort A (aST): Percentage change in tumor size

| End point title | Cohort A (aST): Percentage change in tumor size[5] |
|---|---|

End point description:

Percentage change in tumour size is defined as the reduction from baseline or the increase from baseline in the absence of a reduction in the sum of the longest diameters (or the short axis

measurements for lymph nodes) of the target lesions. A negative change denotes a reduction in target lesion size. In the data presentation table, the arbitary value 9.999, 9.9999 represents the data where data was not calculable as there were insufficient number of participants and the descriptive statistics cannot be calculated.
Molecularly eligible centrally confirmed evaluable for response set included all participants who were Molecularly Eligible Centrally Confirmed with measurable baseline disease and who received at least 1 dose of study intervention. Percentage change in tumor size was conducted every 8 weeks after the start of the treatment up to 1 year, then every 12 weeks until objective disease progression as per RECIST 1.1 or PCWG3 criteria.

| End point type | Secondary |
|---|---|

End point timeframe:

Scan Visits 1 (Week 8), 2 (Week 16), 3 (Week 24), 4 (Week 32), 5 (Week 40), 6 (Week (48), 7 (Week 56)

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No formal hypothesis testing was conducted and therefore has not been presented here.

| **End point values** | Cohort A (aST): 240 mg of Ceralasertib | Cohort A (aST): 160 mg of Ceralasertib | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 5 | 28 | | |
| Units: Percentage change | | | | |
| arithmetic mean (standard deviation) | | | | |
| Week 8 Cohort A: N= 23 Cohort B: N= 4 | 6.2 (± 10.99) | 6.6 (± 22.45) | | |
| Week 16 Cohort A: N= 13 Cohort B: N= 1 | 5.4 (± 9.9999) | -4.7 (± 16.83) | | |
| Week 24 Cohort A: N= 10 Cohort B: N= 0 | 9.999 (± 9.9999) | -12.8 (± 21.47) | | |
| Week 32 Cohort A: N= 5 Cohort B: N= 0 | 9.999 (± 9.9999) | -17.9 (± 34.41) | | |
| Week 40 Cohort A: N= 1 Cohort B: N= 0 | 9.999 (± 9.9999) | -1.1 (± 9.9999) | | |
| Week 48 Cohort A: N= 1 Cohort B: N= 0 | 9.999 (± 9.9999) | -100 (± 9.9999) | | |
| Week 56 Cohort A: N= 1 Cohort B: N= 0 | 9.999 (± 9.9999) | -100 (± 9.9999) | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Cohort A (aST): Progression free survival (PFS)

| End point title | Cohort A (aST): Progression free survival (PFS)[6] |
|---|---|

End point description:

PFS is defined as the time from start of study intervention until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy prior to progression.
Molecularly eligible centrally confirmed set included all participants who were Molecularly Eligible Centrally Confirmed and who received at least 1 dose of study intervention.
Due to an increased frequency and early onset of Grade≥3 hematological toxicity noted among the participants receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg BID starting dose were not included in the efficacy analyses for both study cohorts.

| End point type | Secondary |
|---|---|

End point timeframe:

Up to 2 years 4 months

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No formal hypothesis testing was conducted and therefore has not been presented here.

| **End point values** | Cohort A (aST): 160 mg of Ceralasertib | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 28 | | | |
| Units: Months | | | | |
| median (confidence interval 80%) | 3.7 (1.9 to 5.6) | | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Cohort A (aST): Duration of Radiological response (DoR)

| End point title | Cohort A (aST): Duration of Radiological response (DoR)[7] |
|---|---|

End point description:

DoR is defined as the time from the date of first documented response (confirmed CR/PR) until date of documented progression or death in the absence of disease progression.
Molecularly eligible centrally confirmed evaluable for response set included all participants who were MolecularlyEligible Centrally Confirmed with measurable baseline disease and who received at least 1 dose of study intervention. The number of responders who subsequently progressed or died was 0, therefore, efficacy analysis was not conducted for Duration of response (DoR).

| End point type | Secondary |
|---|---|

End point timeframe:

Up to 2 years 4 months

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No formal hypothesis testing was conducted and therefore has not been presented here.

| **End point values** | Cohort A (aST): 160 mg of Ceralasertib | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 0[8] | | | |
| Units: Months | | | | |
| median (inter-quartile range (Q1-Q3)) | ( to ) | | | |

Notes:

[8] - No subject was analyzed for Duration of Radiological response in Cohort A.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Cohort B (mRCPC): Percentage change in tumor size

| End point title | Cohort B (mRCPC): Percentage change in tumor size[9] |
|---|---|

End point description:

Percentage change in tumour size is defined as the reduction from baseline or the increase from baseline in the absence of a reduction in the sum of the longest diameters (or the short axis measurements for lymph nodes) of the target lesions. A negative change denotes a reduction in target lesion size. Molecularly eligible centrally confirmed evaluable for response set included all participants who were Molecularly Eligible Centrally Confirmed with measurable baseline disease and who received at least 1 dose of study intervention. Percentage change in tumor size was conducted every 8 weeks after the start of the treatment up to 1 year, then every 12 weeks until objective disease progression as per RECIST 1.1 or PCWG3 criteria. Due to an increased frequency and early onset of Grade≥3 hematological toxicity on receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg were not included in the efficacy analyses for both study cohorts.

| End point type | Secondary |
|---|---|

End point timeframe:

Scan Visits 1 (Week 8), 2 (Week 16), 3 (Week 24), 4 (Week 32)

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: No formal hypothesis testing was conducted and therefore has not been presented here.

| **End point values** | Cohort B (mCRPC): 160 mg of Ceralasertib | | | |
|---|---|---|---|---|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 11 | | | |
| Units: Percentage change | | | | |
| arithmetic mean (standard deviation) | | | | |
| Scan Visit 1 (Week 8) N=8 | 2.0 (± 21.35) | | | |
| Scan Visit 2 (Week 16) N=4 | -6.0 (± 9.37) | | | |
| Scan Visit 3 (Week 24) N=2 | -1.4 (± 11.75) | | | |
| Scan Visit 4 (Week 32) N=2 | -5.2 (± 13.21) | | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Cohort A (aST) and B (mCRPC): Number of participants with serious and non-serious adverse events

| End point title | Cohort A (aST) and B (mCRPC): Number of participants with serious and non-serious adverse events |
|---|---|

End point description:

The adverse events as a variable of safety and tolerability after admiration of ceralasertib was determined. CTCAE= Common Terminology Criteria for Adverse Events; IP=investigational product

| End point type | Secondary |
|---|---|

End point timeframe:

Up to 2 years 4 months

| End point values | Cohort A (aST): 240 mg of Ceralasertib | Cohort A (aST): 160 mg of Ceralasertib | Cohort B (mCRPC): 240 mg of Ceralasertib | Cohort B (mCRPC): 160 mg of Ceralasertib |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 8 | 30 | 1 | 15 |
| Units: Participants | | | | |
| All Adverse events (AE) | 8 | 30 | 1 | 15 |
| Any AE possibly related to treatment | 8 | 21 | 1 | 13 |
| Any AE of CTCAE Grade 3 or higher | 6 | 15 | 1 | 8 |
| Any AE of CTCAE grade 3 or higher, related to IP | 4 | 6 | 1 | 5 |
| Any AE with outcome of death | 0 | 0 | 1 | 0 |
| Any AE with outcome = death related to IP | 0 | 0 | 1 | 0 |
| Any SAE (including events with outcome = death) | 6 | 4 | 1 | 4 |
| Any SAE (events outcome =death) related to IP | 3 | 2 | 1 | 1 |
| Any SAE leading to discontinuation of IP | 0 | 1 | 1 | 0 |
| IP-related SAE leading to discontinuation | 0 | 0 | 1 | 0 |
| Any AE leading to discontinuation of IP | 0 | 1 | 1 | 1 |
| IP-related AE leading to discontinuation | 0 | 0 | 1 | 1 |
| Any AE leading to dose modification | 4 | 10 | 1 | 5 |
| Any AE leading to dose reduction | 1 | 4 | 0 | 3 |
| Any AE leading to dose interruption | 4 | 7 | 1 | 3 |
| Any AE leading to dosing cycle delays | 1 | 0 | 0 | 1 |
| Any other significant AEs | 0 | 0 | 0 | 0 |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

| Adverse events information | |
|---|---|
| Timeframe for reporting adverse events: | |
| From Screening (Day -28 to Day -1) Until Follow-up (30 days post last dose) | |
| Adverse event reporting additional description: | |
| Safety analysis consist of all participants who received at least 1 dose of study intervention. | |
| Assessment type | Non-systematic |

| Dictionary used | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 25.1 |

| Reporting groups | |
|---|---|
| Reporting group title | Cohort A (aST): 240 mg of Ceralasertib |
| Reporting group description: | |
| Participants with Ataxia telangiectasia mutated (ATM) altered Advanced solid tumour (aST) received 240 mg of ceralasertib twice daily from Day 1 to Day 14 of 28 days cycle. | |
| Reporting group title | Cohort A (aST): 160 mg of Ceralasertib |
| Reporting group description: | |
| Participants with ATM-altered aST received 160 mg of ceralasertib twice daily from Day 1 to Day 14 of 28 days cycle. | |
| Reporting group title | Cohort B (mCRPC): 240 mg of Ceralasertib |
| Reporting group description: | |
| Participants with ATM-altered Metastatic castration-resistant prostate cancer (mCRPC) received 240 mg of ceralasertib twice daily from Day 1 to Day 14 of 28 days cycle. | |
| Reporting group title | Cohort B (mCRPC): 160 mg of Ceralasertib |
| Reporting group description: | |
| Participants with ATM-altered mCRPC received 160 mg of ceralasertib twice daily from Day 1 to Day 14 of 28 days cycle. | |

| Serious adverse events | Cohort A (aST): 240 mg of Ceralasertib | Cohort A (aST): 160 mg of Ceralasertib | Cohort B (mCRPC): 240 mg of Ceralasertib |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 6 / 8 (75.00%) | 4 / 30 (13.33%) | 1 / 1 (100.00%) |
| number of deaths (all causes) | 0 | 0 | 1 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Investigations | | | |
| Platelet count decreased | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 2 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neutrophil count decreased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| White blood cell count decreased | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Cardiac arrest | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 1 / 1 (100.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Blood and lymphatic system disorders | | | |
| Febrile neutropenia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancytopenia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 30 (3.33%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 2 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anaemia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration | | | |

| | | | |
|---|---|---|---|
| site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 30 (3.33%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Nausea | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 30 (3.33%) | 1 / 1 (100.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 30 (3.33%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 3 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoxia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Rash maculo-papular | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Confusional state | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Device related infection | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 30 (3.33%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| **Serious adverse events** | Cohort B (mCRPC): 160 mg of Ceralasertib | | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 4 / 15 (26.67%) | | |

| | | | |
|---|---|---|---|
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | 0 | | |
| Investigations | | | |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| White blood cell count decreased | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiac disorders | | | |
| Cardiac arrest | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Blood and lymphatic system disorders | | | |
| Febrile neutropenia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pancytopenia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Thrombocytopenia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Anaemia | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal disorders | | | |
| Nausea | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pleural effusion | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 15 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hypoxia | | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Skin and subcutaneous tissue disorders | | | | |
| Rash maculo-papular | | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Psychiatric disorders | | | | |
| Confusional state | | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Infections and infestations | | | | |
| Device related infection | | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pneumonia | | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Sepsis | | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metabolism and nutrition disorders | | | | |
| Decreased appetite | | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 15 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hypoglycaemia | | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| **Non-serious adverse events** | Cohort A (aST): 240 mg of Ceralasertib | Cohort A (aST): 160 mg of Ceralasertib | Cohort B (mCRPC): 240 mg of Ceralasertib |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 8 / 8 (100.00%) | 30 / 30 (100.00%) | 1 / 1 (100.00%) |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 4 / 8 (50.00%) | 8 / 30 (26.67%) | 1 / 1 (100.00%) |
| occurrences (all) | 4 | 8 | 2 |
| Asthenia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 7 / 30 (23.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 7 | 0 |
| Chest pain | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Facial pain | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| oedema peripheral | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 1 / 30 (3.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Pain | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 1 / 30 (3.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Mucosal discolouration | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Reproductive system and breast disorders | | | |
| Penile pain | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pelvic pain | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 2 / 30 (6.67%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 3 / 30 (10.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 2 | 3 | 2 |
| Dyspnoea | | | |
| subjects affected / exposed | 4 / 8 (50.00%) | 4 / 30 (13.33%) | 1 / 1 (100.00%) |
| occurrences (all) | 5 | 5 | 2 |
| Hypoxia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 1 / 30 (3.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Epistaxis | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 1 / 30 (3.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Productive cough | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 2 / 30 (6.67%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psychiatric disorders | | | |

| | | | |
|---|---|---|---|
| Depression | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Insomnia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 1 / 30 (3.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Anxiety | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 1 / 30 (3.33%) | 1 / 1 (100.00%) |
| occurrences (all) | 1 | 1 | 1 |
| Investigations | | | |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 2 / 30 (6.67%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Platelet count increased | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 2 / 30 (6.67%) | 1 / 1 (100.00%) |
| occurrences (all) | 2 | 4 | 1 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 0 | 0 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 2 / 30 (6.67%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 4 / 30 (13.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 7 | 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 3 / 30 (10.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 5 | 0 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 3 / 30 (10.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Gamma-glutamyltransferase increased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Electrocardiogram QT prolonged | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone decreased | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| White blood cell count decreased | | | |
| subjects affected / exposed | 3 / 8 (37.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cardiac disorders | | | |
| Tachycardia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Palpitation | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinus tachycardia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nervous system disorders | | | |
| Dysguesia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dizziness | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 2 / 30 (6.67%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 2 | 0 |
| Peripheral sensory neuropathy | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 8 (12.50%) | 1 / 30 (3.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Dysarthria | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Sensory disturbance | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neuralgia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Headache | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 3 / 30 (10.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 6 / 8 (75.00%) | 8 / 30 (26.67%) | 0 / 1 (0.00%) |
| occurrences (all) | 8 | 10 | 0 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 6 / 30 (20.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 8 | 0 |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Neutropenia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 0 | 0 | 1 |
| Lymph node pain | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Eye disorders | | | |
| Eye pain | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Periorbital oedema | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Scleral haemorrhage | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal distension | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 1 / 30 (3.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 5 / 30 (16.67%) | 1 / 1 (100.00%) |
| occurrences (all) | 1 | 9 | 2 |
| Constipation | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 7 / 30 (23.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 7 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 2 / 30 (6.67%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 9 / 30 (30.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 9 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 3 / 8 (37.50%) | 5 / 30 (16.67%) | 0 / 1 (0.00%) |
| occurrences (all) | 3 | 6 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 5 / 30 (16.67%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 5 | 0 |
| Nausea | | | |
| subjects affected / exposed | 4 / 8 (50.00%) | 13 / 30 (43.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 5 | 14 | 0 |

| | | | |
|---|---|---|---|
| Dysphagia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dyspepsia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dry mouth | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 2 / 30 (6.67%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 4 | 0 |
| Melaena | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Anorectal disorder | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hepatobiliary disorders | | | |
| Hepatic cytolysis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertransaminasaemia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Dry skin | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 3 / 30 (10.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Palmar-plantar erythrodysaesthesia syndrome | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Pruritis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 3 / 30 (10.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Skin mass | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Actinic keratosis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash maculo-papular | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Renal and urinary disorders | | | |
| Proteinuria | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Pollakiuria | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 3 / 30 (10.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Bone pain | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neck pain | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 3 / 30 (10.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Muscular weakness | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 1 | 0 | 2 |
| Pain in extremity | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 1 / 30 (3.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Spinal pain | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Groin pain | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Oral fungal infection | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 2 / 30 (6.67%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| COVID-19 | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Herpes simplex reactivation | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Device related infection | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin infection | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Appetite disorder | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Decreased appetite | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 6 / 30 (20.00%) | 1 / 1 (100.00%) |
| occurrences (all) | 2 | 6 | 2 |
| Dehydration | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 1 / 30 (3.33%) | 1 / 1 (100.00%) |
| occurrences (all) | 1 | 1 | 1 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 3 / 30 (10.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 4 | 0 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hyperphosphataemia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Folate deficiency | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 30 (0.00%) | 0 / 1 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 4 / 30 (13.33%) | 0 / 1 (0.00%) |
| occurrences (all) | 2 | 8 | 0 |

| **Non-serious adverse events** | Cohort B (mCRPC): 160 mg of Ceralasertib | | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 15 / 15 (100.00%) | | |
| General disorders and administration site conditions | | | |

| | | | |
|---|---|---|---|
| Fatigue<br>subjects affected / exposed<br>occurrences (all) | 5 / 15 (33.33%)<br>5 | | |
| Asthenia<br>subjects affected / exposed<br>occurrences (all) | 2 / 15 (13.33%)<br>2 | | |
| Chest pain<br>subjects affected / exposed<br>occurrences (all) | 0 / 15 (0.00%)<br>0 | | |
| Facial pain<br>subjects affected / exposed<br>occurrences (all) | 0 / 15 (0.00%)<br>0 | | |
| oedema peripheral<br>subjects affected / exposed<br>occurrences (all) | 0 / 15 (0.00%)<br>0 | | |
| Pain<br>subjects affected / exposed<br>occurrences (all) | 0 / 15 (0.00%)<br>0 | | |
| Mucosal discolouration<br>subjects affected / exposed<br>occurrences (all) | 1 / 15 (6.67%)<br>1 | | |
| Pyrexia<br>subjects affected / exposed<br>occurrences (all) | 1 / 15 (6.67%)<br>1 | | |
| Reproductive system and breast disorders | | | |
| Penile pain<br>subjects affected / exposed<br>occurrences (all) | 1 / 15 (6.67%)<br>1 | | |
| Pelvic pain<br>subjects affected / exposed<br>occurrences (all) | 0 / 15 (0.00%)<br>0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough<br>subjects affected / exposed<br>occurrences (all) | 0 / 15 (0.00%)<br>0 | | |
| Dyspnoea | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 15 (13.33%) | | |
| occurrences (all) | 2 | | |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Productive cough | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Psychiatric disorders | | | |
| Depression | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Insomnia | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Investigations | | | |
| Weight decreased | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Platelet count increased | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Platelet count decreased | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Electrocardiogram QT prolonged | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Blood thyroid stimulating hormone decreased | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Blood creatinine increased | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| White blood cell count decreased | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injury, poisoning and procedural complications | | | |

| | | | |
|---|---|---|---|
| Contusion<br>subjects affected / exposed<br>occurrences (all) | 0 / 15 (0.00%)<br>0 | | |
| Cardiac disorders<br>Tachycardia<br>subjects affected / exposed<br>occurrences (all)<br><br>Palpitation<br>subjects affected / exposed<br>occurrences (all)<br><br>Sinus tachycardia<br>subjects affected / exposed<br>occurrences (all) | <br><br>0 / 15 (0.00%)<br>0<br><br><br>1 / 15 (6.67%)<br>1<br><br><br>1 / 15 (6.67%)<br>1 | | |
| Nervous system disorders<br>Dysguesia<br>subjects affected / exposed<br>occurrences (all)<br><br>Dizziness<br>subjects affected / exposed<br>occurrences (all)<br><br>Peripheral sensory neuropathy<br>subjects affected / exposed<br>occurrences (all)<br><br>Dysarthria<br>subjects affected / exposed<br>occurrences (all)<br><br>Sensory disturbance<br>subjects affected / exposed<br>occurrences (all)<br><br>Neuropathy peripheral<br>subjects affected / exposed<br>occurrences (all)<br><br>Neuralgia<br>subjects affected / exposed<br>occurrences (all)<br><br>Headache | <br><br>2 / 15 (13.33%)<br>2<br><br><br>2 / 15 (13.33%)<br>2<br><br><br>0 / 15 (0.00%)<br>0<br><br><br>0 / 15 (0.00%)<br>0<br><br><br>1 / 15 (6.67%)<br>1<br><br><br>1 / 15 (6.67%)<br>1<br><br><br>1 / 15 (6.67%)<br>1 | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 15 (13.33%) | | |
| occurrences (all) | 2 | | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 6 / 15 (40.00%) | | |
| occurrences (all) | 8 | | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Leukopenia | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 2 | | |
| Neutropenia | | | |
| subjects affected / exposed | 2 / 15 (13.33%) | | |
| occurrences (all) | 2 | | |
| Lymph node pain | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Eye disorders | | | |
| Eye pain | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Periorbital oedema | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Scleral haemorrhage | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Vision blurred | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Gastrointestinal disorders | | | |
| Abdominal distension | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Diarrhoea | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Constipation | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 2 | | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Vomiting | | | |
| subjects affected / exposed | 2 / 15 (13.33%) | | |
| occurrences (all) | 2 | | |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Nausea | | | |
| subjects affected / exposed | 8 / 15 (53.33%) | | |
| occurrences (all) | 10 | | |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Dry mouth | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Melaena | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Anorectal disorder | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Hepatobiliary disorders | | | |

| | | | |
|---|---|---|---|
| Hepatic cytolysis | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Hypertransaminasaemia | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Skin and subcutaneous tissue disorders | | | |
| Dry skin | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Palmar-plantar erythrodysaesthesia syndrome | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pruritis | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Skin mass | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Rash | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Actinic keratosis | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Rash maculo-papular | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Renal and urinary disorders | | | |
| Proteinuria | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pollakiuria | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Musculoskeletal and connective tissue disorders | | | |

| | | | |
|---|---|---|---|
| Arthralgia | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Bone pain | | | |
| subjects affected / exposed | 2 / 15 (13.33%) | | |
| occurrences (all) | 2 | | |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 2 | | |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Neck pain | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Back pain | | | |
| subjects affected / exposed | 2 / 15 (13.33%) | | |
| occurrences (all) | 2 | | |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Pain in extremity | | | |
| subjects affected / exposed | 2 / 15 (13.33%) | | |
| occurrences (all) | 2 | | |
| Spinal pain | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Groin pain | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Infections and infestations | | | |
| Oral fungal infection | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| COVID-19 | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Herpes simplex reactivation | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 2 | | |
| Rhinitis | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Device related infection | | | |
| subjects affected / exposed | 1 / 15 (6.67%) | | |
| occurrences (all) | 1 | | |
| Skin infection | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Metabolism and nutrition disorders | | | |
| Appetite disorder | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Decreased appetite | | | |
| subjects affected / exposed | 3 / 15 (20.00%) | | |
| occurrences (all) | 3 | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hypocalcaemia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 0 / 15 (0.00%) | | |
| occurrences (all) | 0 | | |

| | | | |
|---|---|---|---|
| Hyperglycaemia<br>subjects affected / exposed<br>occurrences (all) | 2 / 15 (13.33%)<br>2 | | |
| Hyperphosphataemia<br>subjects affected / exposed<br>occurrences (all) | 0 / 15 (0.00%)<br>0 | | |
| Folate deficiency<br>subjects affected / exposed<br>occurrences (all) | 1 / 15 (6.67%)<br>1 | | |
| Hyponatraemia<br>subjects affected / exposed<br>occurrences (all) | 0 / 15 (0.00%)<br>0 | | |

## More information

## Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 12 August 2020 | In the amendment 1, the test "discontinuation" was added to the table title, definition of prolonged Grade 2 toxicity, the text "Grade 2" for thrombocytopenia under Grade 2 events and addition of Grade 3-4 neutropenia or Grade 4 anaemia" under Grade 3-4 toxicity were added. |
| 04 November 2022 | This amendment is considered to be substantial based on the criteria set forth in Article 10(a)<br>of Directive 2001/20/EC of the European Parliament and the Council of the European Union. In Section 6.1 (Intervention after the final DCO) and Section 11.6.7 (Intervention after the Final DCO) text was added to clarify options for continuation of treatment for patients<br>receiving benefit at time of final DCO. |
| 27 May 2024 | New section/text related to study disruption, clarification of sample size following dose reduction to 160 mg BID in the synopsis, Update following dose reduction to 160 mg BID in the schema, to provide clarification for ATM mutation definition in Appendix K. |

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

None reported